Journal
CANCER LETTERS
Volume 349, Issue 2, Pages 120-127Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2014.04.004
Keywords
Neuropilin; Protein-protein interaction; Fully organic inhibitors; Tumor growth inhibition
Categories
Funding
- INCa grant (ANGIOMED)
Ask authors/readers for more resources
Neuropilin-1/-2 (+33 NRPs), VEGF-A(165) co-receptors, are over-expressed during cancer progression. Thus, NRPs targeted drug development is challenged using a multistep in silico/in vitro screening procedure. The first fully non-peptidic VEGF-A(165)/NRPs protein-protein interaction antagonist (IC50= 34 mu M) without effect on pro-angiogenic kinases has been identified (compound-1). This hit showed breast cancer cells anti-proliferative activity (IC50= 0.60 mu M). Compound-1 treated NOG-xenografted mice significantly exerted tumor growth inhibition, which is correlated with Ki-67(low) expression and apoptosis. Furthermore, CD31(+)/CD34(+) vessels are reduced in accordance with HUVEC-tube formation inhibition (IC50= 0.20 mu M). Taking together, compound-1 is the first fully organic inhibitor targeting NRPs. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available